BILL ANALYSIS

HR7861

BEARISH

To amend title XXVII of the Public Health Service Act and the Patient Protection and Affordable Care Act to provide for certain reforms with respect to medical loss ratios and reducing fraudulent enrollment in qualified health plans.

HR7861 (To amend title XXVII of the Public Health Service Act and the Patient Protection and Affordable Care Act to provide for certain reforms with respect to medical loss ratios and reducing fraudulent enrollment in qualified health plans.) has been assessed with a bearish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

3/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR7861 is early-stage, single-cosponsor bill with very low passage probability in current session

If enacted, would compress margins on individual/small group lines for insurers like $ELV, $CI, $HUM

Current stock rallies of 7-40% over 30 days indicate the market is ignoring the legislative risk entirely

Elevance Health has the highest exposure among the three major insurers analyzed

How HR7861 Affects the Market

The sharp rallies in $ELV ($371.61), $CI ($285.75), and $HUM ($241.25) over the past 30 days suggest the market is focused on other fundamentals — possibly rate approvals, enrollment growth, or sector rotation — and is not pricing in HR7861. For investors, this creates a potential asymmetry: if the bill unexpectedly gains committee traction, these stocks could face a 3-8% headline-driven pullback. However, given the early-stage status and long odds, the current rally is likely sustainable on its own merits. Monitor committee scheduling and additional cosponsor additions as leading indicators of true risk.

Bill Details

Metric	Value
Bill Number	HR7861
Market Sentiment	bearish
Event Date	March 9, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR7861 (Care Over Profits Act) proposes raising the minimum MLR from 80% to 85% for individual/small group health plans. The bill is early-stage, referred to committee, and faces long odds, with only one cosponsor and no companion in the Senate. Despite the bearish direct impact on insurer margins, major health insurer stocks have rallied 7-40% over the past 30 days, indicating the market is not pricing in legislative risk.

Full AI Market Analysis

1) What happened and current status: On March 9, 2026, Rep. Barrett (R-MI) introduced HR7861, the Care Over Profits Act. It was referred to the House Energy and Commerce Committee. With 119th Congress now in its second session and only one cosponsor, the bill is at a very early procedural stage with minimal legislative momentum. 2) The money trail: The bill does NOT authorize or appropriate any government funding. It imposes a regulatory mandate — raising the minimum MLR for individual/small group plans from 80% to 85%. This directly compresses insurer profit margins on those lines of business: for every $100 in premium, an insurer can retain at most $15 for administration/profit instead of $20. The mechanism is a mandatory spending floor, not a government outlay. 3) Structural winners and losers: Losers are health insurers with large individual/small group commercial books. Elevance Health ($ELV) has the highest exposure at ~35% of premiums, followed by Cigna ($CI) at ~15-20%, and Humana ($HUM) at ~5-8%. No clear winners from this bill. 4) Real market data analysis: Despite the bearish legislative risk, the three affected insurers have rallied sharply over the past 30 days: $ELV +26.94%, $CI +7.12%, $HUM +39.13%. These moves suggest the market is pricing in other tailwinds — likely positive earnings reports, 2026 rate approval cycles, or macro rotation into healthcare — rather than assigning probability to HR7861 passage. The 7-day changes (ELV +7.79%, CI +3.66%, HUM +12.08%) show continued momentum. 5) Timeline: The bill requires committee mark-up in House Energy and Commerce, full House vote, Senate companion introduction and passage, then presidential signature. With a single cosponsor and early stage referral, probability of passage in 2026 is very low (<10%). If reintroduced with broader support, it could gain traction in a 120th Congress.